Trial document



drksid header

  DRKS00000111

Trial Description

start of 1:1-Block title

Title

Etiology, Epidemiology and Treatment of Diarrhea and Enterocolitis in Hemato-oncological High Risk Patients (EpiDi)

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

EpiDi

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

In patients with cancer, gastrointestinal infections with certain bacteria are associated with severe complications, such as inflammation of the colon, loss of the barrier function of the colonic wall, generalized infection and death.
Particularly a certain bacterium called Clostridium difficile seems to play a crucial role in this setting. A new strain of this bacterium, called PCR Ribotyp 027 seems to entail complications or death more frequently than previously observed strains.
For this reason, many physicians decide to administer calculated antibiotic therapy with oral metronidazole to patients with abdominal pain or diarrhea after after administration of chemotherapy. There are no results from clinical trials, suporting this strategy. Nevertheless, its practice is recommended by the Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie (AGIHO) of the Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO).
Whether patients truely benefit from this treatment can only be assessed in a controlled, randomized clinical trial. At the moment it's not possible to design such a study, because epidemiological data on does not suffice to calculate the number of patients that would be needed to complete such a trial.
In a multicentric observational study, the parameters needed for a reliable case calculation will be documented to assess the feasibility of a clinical trial in this setting.
In a multicentric observational study, the parameters needed for a reliable case calculation will be documented to assess the feasibility of a clinical trial in this setting.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

In hemato-oncological high risk patients, abdominal infections with anaerobic bacteria are associated with severe complications, such as enterocolitis, toxic megacolon, perforation, septic shock and death.
Clostridium difficile seems to play a crucial role in this setting. Current reports on the course of abdominal infections with hypervirulent Clostridium difficile PCR Ribotyp 027 strains in Germany and other regions of Europe reported a dramatic rise in morbidity and lethality in association with this pathogen.
For this reason, neutropenic patients with diarrhea and/or other signs of abdominal infection are often provided with an empiric course of oral Metronidazole. Even though this strategy is not supported by evidence from clinical trials, its practice is recommended by the Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie (AGIHO) of the Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO).
The clinical efficacy of this strategy can only be assessed in clinical trials. Due to the heterogenicity of prior studies on the epidemiology and course of these infections, a reliable case calculation is currently not possible.
In a multicentric, prospective observational study, the parameters needed for a reliable case calculation will be documented to assess the feasibility of a clinical trial in this setting.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00000111
  •   2009/06/16
  •   [---]*
  •   yes
  •   Approved
  •   09-094, Ethik-Kommission der Medizinischen Fakultät der Universität zu Köln
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Haematologic malignancy
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   No intervention
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Supportive care
  •   Single (group)
  •   N/A
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Incidence of abdominal complications after chemotherapy

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Effect of empiric metronidazole or vancomycin on the incidence of abdominal complications

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2009/06/03
  •   400
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Neutropenia >= 5 days, defined as <500 neutrophils/microL. If no differential blood count available, use <1000 leukocytes/microL

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

a) Neutropenia <5 days, defined as <500 neutrophils/microL. If no differential blood count available, use <1000 leukocytes/microL
b) Patients with Colitis ulcerosa, Morbus Crohn or other inflammatory diseases of the colon
c) Patients with diarrhea at admission
d) Patienten, receiving prophylaxis with metronidazole (per os or intravenous) or vancomycin (per os)

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Uniklinik Köln
    • Kerpener Str. 62
    • 50937  Köln
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   +49 221 478 6494
    •   +49 221 478 3611
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Uniklinik Köln, Klinik I für Innere Medizin, Studienzentrum 2 für Infektiologie
    • Ms.  Dr. med.  Maria J.G.T.  Rüping 
    • Kerpener Str. 62
    • 50937  Köln
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Uniklinik Köln, Klinik I für Innere Medizin, Studienzentrum 2 für Infektiologie
    • Ms.  Dr. med.  Maria J.G.T.  Rüping 
    • Kerpener Str. 62
    • 50937  Köln
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • DFG
    • Ms.  Christiane  Krämer 
    • 53170  Bonn
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   +49 228/885-1
    •   +49 228/885-2777
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.